IN8bio, Inc. (INAB) is a biotechnology company dedicated to developing innovative therapies for people fighting against serious diseases, including cancer. The company engages in essential research and development efforts with the main focus on the utilization of genetically modified gamma delta T cells, a kind of white blood cell. The resulting therapies ideally enable a person's immune system to combat diseases more effectively.
IN8bio emerged as a strong player in the world of biotech after its successful IPO in October 2020. It was established by ex-executives of Kite, another biotech company, and is located in New York, United States. Although fairly new, INAB has already demonstrated its potential and commitment to making a significant positive impact on the health sector.
The company’s cutting-edge portfolio includes programs that target glioblastoma and acute leukemias, two aggressive types of cancers. Their INB-100 program for Glioblastoma, an aggressive, incurable form of brain cancer, is a direct gamma-delta T cell therapeutic, which is in phase I of clinical trials. Meanwhile, their INB-200 program for Acute Leukemias is an allogeneic gamma-delta T cell therapeutic for patients undergoing a bone marrow transplant and it's in phase I of clinical development as well.
Another key element of their approach is the use of Drug Resistant Immunotherapy (DRI) technology platform. This unique technology allows the genetic modification of cancer patient’s T cells to make them resistant to specific chemotherapy drugs. Thus, allowing concurrent administration of cancer-directed chemotherapy and immune T cells.
IN8bio places great importance on collaborations with other biotech companies and research institutions. Through these partnerships, they leverage complementary resources and expertise to accelerate the development and commercialization of their cell therapies.
Despite the risks and uncertainties that come with biotech and pharmaceutical industries — especially in the development phase — IN8bio’s goal is clear: to develop effective and tolerable therapies that can be successfully integrated into the standard of care and markedly improve the outcomes for patients fighting serious diseases. Innovating solutions for diseases like cancer, IN8bio makes a mark as a forward-thinking, steadfast biotech player. The company continues to work on assembling a strong clinical, scientific, and operational team while securing the necessary financial resources to advance its programs and fulfill its mission to help patients.